These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 29467456)

  • 1. Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma.
    Sun W; He B; Yang B; Hu W; Cheng S; Xiao H; Yang Z; Wen X; Zhou L; Xie H; Shen X; Wu J; Zheng S
    Lab Invest; 2018 Jun; 98(6):734-744. PubMed ID: 29467456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-scale CRISPR activation screening identifies a role of LRP8 in Sorafenib resistance in Hepatocellular carcinoma.
    Cai J; Chen J; Wu T; Cheng Z; Tian Y; Pu C; Shi W; Suo X; Wu X; Zhang K
    Biochem Biophys Res Commun; 2020 Jun; 526(4):1170-1176. PubMed ID: 32312520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC.
    Chan YT; Wu J; Lu Y; Li Q; Feng Z; Xu L; Yuan H; Xing T; Zhang C; Tan HY; Feng Y; Wang N
    Mol Cancer; 2024 Apr; 23(1):74. PubMed ID: 38582885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
    Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
    Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
    Wang C; Wang H; Lieftink C; du Chatinier A; Gao D; Jin G; Jin H; Beijersbergen RL; Qin W; Bernards R
    Gut; 2020 Apr; 69(4):727-736. PubMed ID: 31519701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide CRISPR knockout screens identify ADAMTSL3 and PTEN genes as suppressors of HCC proliferation and metastasis, respectively.
    Zhou X; Li R; Jing R; Zuo B; Zheng Q
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1509-1521. PubMed ID: 32266537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress.
    Lu Y; Chan YT; Wu J; Feng Z; Yuan H; Li Q; Xing T; Xu L; Zhang C; Tan HY; Lee TK; Feng Y; Wang N
    Drug Resist Updat; 2023 Nov; 71():101015. PubMed ID: 37924725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.
    Wei L; Lee D; Law CT; Zhang MS; Shen J; Chin DW; Zhang A; Tsang FH; Wong CL; Ng IO; Wong CC; Wong CM
    Nat Commun; 2019 Oct; 10(1):4681. PubMed ID: 31615983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
    Su WL; Chuang SC; Wang YC; Chen LA; Huang JW; Chang WT; Wang SN; Lee KT; Lin CS; Kuo KK
    Cancer Biomark; 2020; 28(3):341-350. PubMed ID: 32390596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
    Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
    Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.
    Chen Y; Li L; Lan J; Cui Y; Rao X; Zhao J; Xing T; Ju G; Song G; Lou J; Liang J
    Mol Cancer; 2022 Jan; 21(1):11. PubMed ID: 34983546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma.
    Yoo JJ; Yu SJ; Na J; Kim K; Cho YY; Lee YB; Cho EJ; Lee JH; Kim YJ; Youn H; Yoon JH
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
    Tan W; Luo X; Li W; Zhong J; Cao J; Zhu S; Chen X; Zhou R; Shang C; Chen Y
    EBioMedicine; 2019 Feb; 40():446-456. PubMed ID: 30594557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
    Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
    Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for HCC target discovery.
    Molina-Sánchez P; Lujambio A
    Aging (Albany NY); 2017 Apr; 9(4):1088-1089. PubMed ID: 28455974
    [No Abstract]   [Full Text] [Related]  

  • 19. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids.
    Wang S; Wang Y; Xun X; Zhang C; Xiang X; Cheng Q; Hu S; Li Z; Zhu J
    J Exp Clin Cancer Res; 2020 Jan; 39(1):22. PubMed ID: 31992334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na
    Jiang W; Li G; Li W; Wang P; Xiu P; Jiang X; Liu B; Sun X; Jiang H
    Sci Rep; 2018 Jun; 8(1):9706. PubMed ID: 29946188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.